News

Archive

Stay updated with the latest news and developments from Topas Therapeutics, including corporate announcements, clinical trial progress, and scientific advancements in immunotherapy research.

5 May 2026 │ Scientific Publication

Antigen-specific tolerance and control of autoimmunity effected by liver sinusoidal endothelial cells is unimpaired in liver fibrosis

12 March 2026 │ Scientific Publication

Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading

29 January 2026 │ Scientific Poster

Antigen-specific immune modulation with liver-targeting nanoparticles fosters immune protective regulatory T cells to delay Type 1 Diabetes

7 August 2025 │ Scientific Publication

Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus

6 May 2025 │ Press Release

Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients

5 May 2025 │ Topas in the News

Endpoints News – Exclusive: Topas claims success in early test of ‘immune tolerance’ therapy for celiac disease.

24 April 2025 │ Press Release

Topas Therapeutics Announces Presentation of Phase 2a Data for TPM502 in Celiac Disease at Digestive Disease Week® 2025 in San Diego

17 March 2025 │ Press Release

Topas Therapeutics Publishes Foundational Data Demonstrating Tolerance Induction by its Proprietary Nanoparticle Platform in Frontiers in Immunology

17 March 2025 │ Scientific Publication

Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models

22 November 2024 │ Topas in the News

Going Public -“We still believe we’re an undiscovered gem” Charting the Future of Immune Tolerance: Insights from the CEO of TOPAS

16 October 2024 │ Topas in the News

Drug Target Review – Women in STEM with Cristina de Min

15 October 2024 │ Press Release

Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial Evaluating TPM502 in Patients with Celiac Disease

28 June 2024 │ Topas in the News

European Pharmaceutical Review – The Promise and Hurdles of Restoring Immune Tolerance

7 May 2024 │ Press Release

Topas Therapeutics Appoints Hugo Fry as CEO

Events

Sixth Newcastle Therapeutic Tolerance Workshop

Newcastle upon Tyne, UK

29 June – 3 July 2026

Info

Connect with our team and learn how we are transforming the treatment of autoimmune diseases